All In Biotech

Drug Trial Radar · NCT04557956

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination With Dual BRAF/MEK Inhibition in Patients With BRAF- Mutated Metastatic Melanoma Who Progressed on Prior BRAF/MEK Inhibitor Therapy

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

16

Actual

Start

Aug 19, 2021

Primary completion

Oct 15, 2025

Study completion Mar 11, 2027

Sponsor

Sponsor type
NIH
First posted
Sep 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I/II trial investigates the best dose, possible benefits and/or side effects of tazemetostat in combination with dabrafenib and trametinib in treating patients with melanoma that has a specific mutation in the BRAF gene (BRAFV600) and that has spread from where it first started (primary site) to other places in the body (metastatic). Tazemetostat, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving tazemetostat in combination with dabrafenib and trametinib may stabilize BRAFV600 mutated melanoma.

Conditions

  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • Metastatic Melanoma

Interventions

  • Biopsy ProcedureProcedure

    Undergo tumor biopsy

  • Computed TomographyProcedure

    Undergo CT scan

  • Dabrafenib MesylateDrug

    Given PO

  • Echocardiography TestProcedure

    Undergo ECHO

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • Tazemetostat HydrobromideDrug

    Given PO

  • Trametinib Dimethyl SulfoxideDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Phase 2 Dose (Phase I)Time frame: The DLT observation window is 30 days
  2. Median Progression-free Survival (PFS) (Phase II)Time frame: At 6 and 12 months

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • UM Sylvester Comprehensive Cancer Center at Aventura

    Aventura, Florida

  • UM Sylvester Comprehensive Cancer Center at Coral Gables

    Coral Gables, Florida

  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach

    Deerfield Beach, Florida

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida

  • UM Sylvester Comprehensive Cancer Center at Plantation

    Plantation, Florida

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Siteman Cancer Center at Saint Peters Hospital

    City of Saint Peters, Missouri

  • Siteman Cancer Center at West County Hospital

    Creve Coeur, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Siteman Cancer Center-South County

    St Louis, Missouri

  • Siteman Cancer Center at Christian Hospital

    St Louis, Missouri

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Huntsman Cancer Institute/University of Utah

    Salt Lake City, Utah

  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

    Madison, Wisconsin

  • University of Wisconsin Carbone Cancer Center - University Hospital

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.